FDA Releases Software Tips for Safer Medical Devices
Published Date: 9/24/2025
Notice
Summary
The FDA just released new guidance to help medical device makers use computer software safely and smartly during production and quality checks. This update encourages using fresh tech to make devices better and faster while keeping everything legal and safe. If you work with medical device software, get ready to follow these new tips to stay ahead and keep patients happy!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA issues software-assurance recommendations
The FDA released final guidance called "Computer Software Assurance for Production and Quality System Software" that gives recommendations on computer software assurance for computers and automated data processing systems used in medical device production and quality systems. If you make or run medical device production or quality-system software, this guidance tells you recommended practices to follow.
Guidance aims to expand patient access
The FDA says these recommendations are intended to help foster adoption of innovative technologies and promote patient access to high-quality medical devices. The guidance also says it should help manufacturers keep pace with rapidly changing technology while promoting compliance with FDA laws and regulations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-18465, Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Partially Closed Meeting
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is holding a two-day virtual meeting on January 26-27, 2026. The first day is open to the public and will share updates and scientific talks, while the second day is closed to review grant applications confidentially. Researchers and the public can join or send comments, with no cost to attend and easy online access.
Next: 2025-18470, New Functionality Pertaining to Electronic Refunds in the Automated Commercial Environment
U.S. Customs and Border Protection is making it easier for businesses to get electronic refunds by adding a new ACH Refund Authorization tab in the ACE Portal. This means faster, smoother refunds through Automated Clearinghouse (ACH) payments. If you import goods, get ready to save time and possibly speed up your money back starting soon!